Madrigal Pharmaceuticals Posts $958.4M 2025 Revenue, Q4 Sales Triple Year-Ago
Madrigal Pharmaceuticals posted record 2025 net sales of $958.4 million, with fourth-quarter revenue of $321.1 million—more than triple last year’s quarterly figure—and boosted its Rezdiffra patient base to over 36,250. The company expanded its pipeline to more than 10 programs, secured Rezdiffra patent protection until 2045 and launched in Germany.
1. Record 2025 Financial Results
Madrigal achieved full-year net sales of $958.4 million in 2025, driven by the Rezdiffra launch. Fourth-quarter revenue reached $321.1 million—more than triple the prior-year quarter—and the Rezdiffra patient base expanded to over 36,250 by year-end, up from approximately 29,500 in Q3.
2. Pipeline Expansion and Patent Extension
During 2025, the company diversified from a single-product focus to a portfolio of more than 10 development programs, including an oral GLP-1 receptor agonist, the Phase 2 DGAT-2 inhibitor ervogastat and six preclinical siRNA candidates. Madrigal also secured patent exclusivity for Rezdiffra through 2045.
3. International Rollout and Future Outlook
Madrigal initiated its first international launch in Germany and projects continued double-digit MASH market growth in 2026 despite gross-to-net impacts rising toward 30%. The United States remains the primary growth engine with broad first-line insurance access, while the MAESTRO-NASH cirrhosis trial is on track to report data in 2027.